Please select the option that best describes you:

For NSCLC patients who are polymetastatic who then become and remain oligometastatic, is there a role for local ablative RT to the primary and metastatic sites?  

If so what dose/fractionation would you use?



Answer from: Radiation Oncologist at Community Practice
Sign in or Register to read more

Answer from: Radiation Oncologist at Academic Institution
Comments
Radiation Oncologist at UCLA | VA Greater Los Angeles Healthcare System
Correct. Sites of residual visible disease after u...
Sign in or Register to read more

Answer from: Radiation Oncologist at Academic Institution
Sign in or Register to read more